Loading…
Management of cerebral azole-resistant A. fumigatus infection. A role for intraventricular liposomal-amphotericin B?
In the pre-azole era, central nervous system (CNS) infections with Aspergillus had a dismal outcome. Survival improved with voriconazole but CNS infections caused by azole-resistant A. fumigatus is precluding its use. Intravenous liposomal-amphotericin B (L-AmB) is the preferred treatment option for...
Saved in:
Published in: | Journal of global antimicrobial resistance. 2020-04 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | In the pre-azole era, central nervous system (CNS) infections with Aspergillus had a dismal outcome. Survival improved with voriconazole but CNS infections caused by azole-resistant A. fumigatus is precluding its use. Intravenous liposomal-amphotericin B (L-AmB) is the preferred treatment option for azole-resistant CNS infections but has suboptimal brain concentrations.
We describe three patients with biopsy proven CNS aspergillosis where intraventricular L-AmB is added to systemic therapy. 2 patients with azole-resistant and 1 patient with azole-susceptible CNS aspergillosis were treated with intraventricular L-AmB at a dose of 1 mg weekly.
We describe 3 patients successfully treated with a combination of intravenous and intraventricular L-AmB. All three patients survived but one patient has serious headache, most likely not related to this treatment.
Intraventricular L-AmB may have a role in the treatment of therapy-refractory CNS aspergillosis when added to systemic therapy. |
---|---|
ISSN: | 2213-7173 |